Form 4: Nautilus Biotechnology Executive Granted Stock Options
SEC Form 4 Filing
Nicholas A. Nelson, CBO & Senior VP of Business Development at Nautilus Biotechnology, Inc., was granted stock options for 160,000 shares on March 3, 2025, according to a Form 4 filing.
Summary
- Nicholas A. Nelson, the Chief Business Officer & Senior VP of Business Development at Nautilus Biotechnology, Inc., was granted stock options.
- The transaction occurred on March 3, 2025.
- Nelson received options to purchase 160,000 shares of common stock at an exercise price of $1.24 per share.
- The options vest over a period of 48 months, with 25% vesting on the first anniversary of January 1, 2025, and the remainder vesting monthly thereafter.
- The options expire on March 3, 2035.
- A Power of Attorney was executed on February 24, 2025, granting certain individuals the authority to act on Nelson's behalf in SEC filings.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.
Positives
- The grant of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
- Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
- The vesting schedule of 48 months is also typical, aligning with industry norms for incentivizing long-term performance.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the executive to drive company performance.
- Employees may see the grant as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| February 24, 2025 | Date of execution of Power of Attorney. |
| January 1, 2025 | Vesting Commencement Date for the stock options. |
| March 3, 2025 | Date of the stock option grant. |
| March 4, 2025 | Date of signature for the Form 4 filing. |
| March 3, 2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.